Opcon's main business is orthokeratology, accounting for 68% of operating income, which is a proper main business. Relying on this unique "trajectory", in recent years, both the company's performance and the stock price response can be described as "very good".

Opcom has not been listed for a long time, but its performance has been very good. Since 20 16, the year-on-year growth rate of operating income has been higher than 30%, and the year-on-year growth rate of net profit has been higher than 25%. The level of return on net assets is not as high as your level of more than 20%. The asset-liability ratio is lower than 15% all the year round, and the gross sales margin is higher than 75% all the year round. From a fundamental point of view, it can be regarded as a good company and a high-quality stock in the A-share market.

The performance is good, and the natural stock price is also very good. Since the listing of 20 17, the stock price has risen by 16 times. In the past two years, the annual growth rate of stock price has reached 300%, and the low point to the high point has reached 500%. This year, it has increased by 80%. It can be said that in recent years, the big bull stocks in the A-share market have risen more than Aier Ophthalmology, which is also a big bull stock.